Literature DB >> 25337052

Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosis.

Mio Nakamura1, Mark Morris1, Mirela Cerghet1, Lonni Schultz1, Stanton Elias1.   

Abstract

BACKGROUND: Magnetic resonance imaging (MRI) is widely used in clinical practice, and "abnormal brain MRI" findings often prompt assessment for multiple sclerosis (MS), even when there are no symptoms suggestive of the disease. Despite several studies involving individuals with "radiologically isolated syndrome" (RIS), little is known about what factors might predict future development of MS. The objective of this study was to longitudinally evaluate clinical and MRI characteristics of people who presented to an MS clinic because of incidental abnormal MRI findings but did not have typical symptoms of MS, in order to assess risk factors for developing MS.
METHODS: Thirty consecutive patients presenting to an MS clinic for evaluation of abnormal MRI findings were enrolled in the study. Clinical and paraclinical data, including MRI results, were reviewed. Magnetic resonance imaging findings of T2 hyperintensities measuring more than 3 mm in diameter and fulfilling at least three out of four Barkhof criteria, with or without gadolinium-enhancing lesions, were considered to be suggestive of MS.
RESULTS: The median follow-up time was 5.5 years. No participants without MRI findings suggestive of MS were diagnosed with MS (P = .005). Fifteen participants had MRI findings suggestive of MS. Seven of the 15 (47%) were diagnosed with MS on follow-up. Cerebrospinal fluid (CSF) testing results were available for 15 participants. Abnormal results were found in six participants, of whom five (83%) also had MRI findings suggestive of MS. Only two of the nine (22%) participants with normal CSF results (P = .04) had MRI findings suggestive of MS.
CONCLUSIONS: In our cohort, none of the participants without MRI findings suggestive of MS developed MS. The participants with MRI findings suggestive of MS were more likely to develop symptoms and MRI changes typical of MS on follow-up.

Entities:  

Year:  2014        PMID: 25337052      PMCID: PMC4204370          DOI: 10.7224/1537-2073.2013-016

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  32 in total

1.  Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: the subclinical stage of primary progressive multiple sclerosis may last 10 years.

Authors:  G V McDonnell; J Cabrera-Gomez; D B Calne; D K B Li; J Oger
Journal:  Mult Scler       Date:  2003-03       Impact factor: 6.312

2.  Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome.

Authors:  D T Okuda; E M Mowry; B A C Cree; E C Crabtree; D S Goodin; E Waubant; D Pelletier
Journal:  Neurology       Date:  2011-01-26       Impact factor: 9.910

Review 3.  Radiologically isolated syndrome--incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review.

Authors:  Tobias Granberg; Juha Martola; Maria Kristoffersen-Wiberg; Peter Aspelin; Sten Fredrikson
Journal:  Mult Scler       Date:  2012-07-03       Impact factor: 6.312

Review 4.  Atypical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at necropsy.

Authors:  J G Phadke; P V Best
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-05       Impact factor: 10.154

5.  Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study.

Authors:  F E de Leeuw; J C de Groot; E Achten; M Oudkerk; L M Ramos; R Heijboer; A Hofman; J Jolles; J van Gijn; M M Breteler
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

Review 6.  Magnetic resonance imaging in multiple sclerosis: the role of conventional imaging.

Authors:  Nancy L Sicotte
Journal:  Neurol Clin       Date:  2011-05       Impact factor: 3.806

7.  'Subclinical MS': follow-up of four cases.

Authors:  B Hakiki; B Goretti; E Portaccio; V Zipoli; M P Amato
Journal:  Eur J Neurol       Date:  2008-08       Impact factor: 6.089

8.  Migraine as a risk factor for subclinical brain lesions.

Authors:  Mark C Kruit; Mark A van Buchem; Paul A M Hofman; Jacobus T N Bakkers; Gisela M Terwindt; Michel D Ferrari; Lenore J Launer
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  3 in total

Review 1.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

2.  Reducing costs while enhancing quality of care in MS.

Authors:  Ilya Kister; John R Corboy
Journal:  Neurology       Date:  2016-09-02       Impact factor: 9.910

3.  A prospective study of patients with brain MRI showing incidental t2 hyperintensities addressed as multiple sclerosis: a lot of work to do before treating.

Authors:  Christine Lebrun; Mikael Cohen; Annabelle Chaussenot; Lydiane Mondot; Stephane Chanalet
Journal:  Neurol Ther       Date:  2014-12-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.